Patents by Inventor Xinye YANG
Xinye YANG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230002400Abstract: An amorphous form of a nitrogen-containing tricyclic compound and a use thereof, a pharmaceutical composition containing the compound in the amorphous form, and the use of the compound in the amorphous form or the pharmaceutical composition in the preparation of a drug for preventing, treating or alleviating FXR-mediated diseases in a patient.Type: ApplicationFiled: November 27, 2020Publication date: January 5, 2023Applicant: SUNSHINE LAKE PHARMA CO., LTD.Inventors: Xinye YANG, Liang CHEN, Yuefeng SHAN, Xiaojun WANG
-
Publication number: 20220389024Abstract: A crystalline form A of a nitrogen-containing tricyclic compound shown in formula (I), a pharmaceutical composition containing the crystalline form A, and the use of the crystalline form A or the pharmaceutical composition in the preparation of a medication for preventing, treating or relieving an FXR-mediated disease of a patient.Type: ApplicationFiled: November 27, 2020Publication date: December 8, 2022Applicant: SUNSHINE LAKE PHARMA CO., LTD.Inventors: Yuefeng SHAN, Liang CHEN, Xinye YANG, Xiaojun WANG
-
Publication number: 20220267346Abstract: Thienopyrimidine derivative having stereo configurations and use thereof in medicine. Also included are pharmaceutical compositions of the compounds. The compounds or pharmaceutical compositions may be used to inhibit acetyl-CoA carboxylase (ACC). A method for preparing the compounds and the pharmaceutical compositions, and use thereof in treatment or prevention of diseases associated with ACC regulation of mammals, in particular, humans.Type: ApplicationFiled: July 2, 2019Publication date: August 25, 2022Applicant: SUNSHINE LAKE PHARMA CO., LTD.Inventors: Zheng GU, Wanjun TANG, Xinye YANG, Xuli WANG, Weihui YUAN, Yunzeng CUI, Wen YANG, Jianyu LIU, Yingjun ZHANG
-
Patent number: 11208418Abstract: Nitrogenous tricyclic compounds and uses thereof in medicine, in particular, a novel nitrogenous tricyclic compound used as an FXR active regulator and a stereoisomer, a geometrical isomer, a tautomer, a N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, and use of the compound in the manufacture of a drug for treating a disease and/or disorder regulated by FXR. A pharmaceutically acceptable composition containing the compound and a method of treating a disease and/or disorder mediated by FXR comprising administering the compound or pharmaceutical composition thereof.Type: GrantFiled: January 28, 2019Date of Patent: December 28, 2021Assignee: SUNSHINE LAKE PHARMA CO., LTD.Inventors: Xinye Yang, Xiaojun Wang, Junwen Wu, Hong Chen, Shengtian Cao, Yingjun Zhang
-
Publication number: 20200392146Abstract: Nitrogenous tricyclic compounds and uses thereof in medicine, in particular, a novel nitrogenous tricyclic compound used as an FXR active regulator and a stereoisomer, a geometrical isomer, a tautomer, a N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, and use of the compound in the manufacture of a drug for treating a disease and/or disorder regulated by FXR. A pharmaceutically acceptable composition containing the compound and a method of treating a disease and/or disorder mediated by FXR comprising administering the compound or pharmaceutical composition thereof.Type: ApplicationFiled: January 28, 2019Publication date: December 17, 2020Applicant: SUNSHINE LAKE PHARMA CO., LTD.Inventors: Xinye YANG, Xiaojun WANG, Junwen WU, Hong CHEN, Shengtian CAO, Yingjun ZHANG
-
Patent number: 10759812Abstract: The present invention relates to a thienopyrimidine derivative and use thereof in medicine, and also to a pharmaceutical composition containing the compound. The compound or pharmaceutical composition is used for inhibiting acetyl-CoA carboxylase (ACC). The present invention also relates to a method of preparing such compound and pharmaceutical composition, as well as their use in the treatment or prevention of diseases regulated by acetyl-CoA carboxylase in mammals, especially in humans.Type: GrantFiled: January 22, 2018Date of Patent: September 1, 2020Assignee: Sunshine Lake Pharma Co., Ltd.Inventors: Wanjun Tang, Xinye Yang, Zheng Gu, Chenlu Li, Zongyuan Zhang, Zhifu Wan, Xiaojun Wang, Yingjun Zhang
-
Patent number: 10562910Abstract: A nitrogen-containing tricyclic compound which acts as modulator of FXR, or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, and the use of the compound for the treatment of disease and/or condition mediated by FXR are described. And a pharmaceutical composition containing the compound disclosed herein and a method of treatment of disease and/or condition mediated by FXR comprising administering the compound or the pharmaceutical composition thereof are also described.Type: GrantFiled: August 2, 2017Date of Patent: February 18, 2020Assignee: NORTH & SOUTH BROTHER PHARMACY INVESTMENT COMPANY LIMITEDInventors: Xiaojun Wang, Xinye Yang, Junwen Wu, Shaohui Xiong, Shengqiang Pan, Shengtian Cao, Yingjun Zhang
-
Publication number: 20190352311Abstract: The present invention relates to a thienopyrimidine derivative and use thereof in medicine, and also to a pharmaceutical composition containing the compound. The compound or pharmaceutical composition is used for inhibiting acetyl-CoA carboxylase (ACC). The present invention also relates to a method of preparing such compound and pharmaceutical composition, as well as their use in the treatment or prevention of diseases regulated by acetyl-CoA carboxylase in mammals, especially in humans.Type: ApplicationFiled: January 22, 2018Publication date: November 21, 2019Applicants: SUNSHINE LAKE PHARMA CO., LTD., NORTH & SOUTH BROTHER PHARMACY INVESTMENT COMPANY LIMITEDInventors: Wanjun TANG, Xinye YANG, Zheng GU, Chenlu LI, Zongyuan ZHANG, Zhifu WAN, Xiaojun WANG, Yingjun ZHANG
-
Publication number: 20190169203Abstract: A nitrogen-containing tricyclic compound which acts as modulator of FXR, or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, and the use of the compound for the treatment of disease and/or condition mediated by FXR are described. And a pharmaceutical composition containing the compound disclosed herein and a method of treatment of disease and/or condition mediated by FXR comprising administering the compound or the pharmaceutical composition thereof are also described.Type: ApplicationFiled: August 2, 2017Publication date: June 6, 2019Applicant: SUNSHINE LAKE PHARMA CO., LTD.Inventors: Xiaojun WANG, Xinye YANG, Junwen WU, Shaohui XIONG, Shengqiang PAN, Shengtian CAO, Yingjun ZHANG
-
Patent number: 10266496Abstract: Carboxy-substituted (hetero)aryl derivatives, pharmaceutical compositions comprising these compounds, and methods of preparing such compounds and compositions are provided. The compounds or compositions are useful in inhibiting xanthine oxidase and urate anion transporter 1, and also can be used in the treatment or prevention of diseases associated with high blood uric acid level in mammals, especially humans.Type: GrantFiled: August 31, 2016Date of Patent: April 23, 2019Assignee: SUNSHINE LAKE PHARMA CO., LTD.Inventors: Xinye Yang, Changwei Huang, Facheng Ma, Ji Zhang, Xiaojun Wang, Yingjun Zhang
-
Patent number: 10183917Abstract: The present invention relates to novel tricyclic compounds which can bind to FXR and act as modulators of the FXR, or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, and the uses of the compounds for the treatment of diseases and/or conditions mediated by FXR. The invention further provides a pharmaceutical composition containing the compound disclosed herein and a method of treatment of diseases and/or conditions mediated by FXR comprising administering the compound or the pharmaceutical composition.Type: GrantFiled: February 5, 2016Date of Patent: January 22, 2019Assignee: SUNSHINE LAKE PHARMA CO., LTD.Inventors: Xiaojun Wang, Xinye Yang, Shengqiang Pan, Rui Guo, Junwen Wu, Yingjun Zhang, Changchung Cheng
-
Publication number: 20180230102Abstract: Carboxy-substituted (hetero)aryl derivatives, pharmaceutical compositions comprising these compounds, and methods of preparing such compounds and compositions are provided. The compounds or compositions are useful in inhibiting xanthine oxidase and urate anion transporter 1, and also can be used in the treatment or prevention of diseases associated with high blood uric acid level in mammals, especially humans.Type: ApplicationFiled: August 31, 2016Publication date: August 16, 2018Applicant: SUNSHINE LAKE PHARMA CO., LTD.Inventors: Xinye YANG, Changwei HUANG, Facheng MA, Ji ZHANG, Xiaojun WANG, Yingjun ZHANG
-
Publication number: 20180030003Abstract: The present invention relates to novel tricyclic compounds which can bind to FXR and act as modulators of the FXR, or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, and the uses of the compounds for the treatment of diseases and/or conditions mediated by FXR. The invention further provides a pharmaceutical composition containing the compound disclosed herein and a method of treatment of diseases and/or conditions mediated by FXR comprising administering the compound or the pharmaceutical composition.Type: ApplicationFiled: February 5, 2016Publication date: February 1, 2018Applicant: Sunshine Lake Pharma Co., Ltd.Inventors: Xiaojun WANG, Xinye YANG, Shengqiang PAN, Rui GUO, Junwen WU, Yingjun ZHANG, Changchung CHENG